

Conclusion: Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD.

Matteo Bargagli, Nasser Dhayat, Manuel Anderegg, Mariam Semmo, et al. ***Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.*** CJASN doi: 10.2215/CJN.13861119. **Visual Abstract by Aakash Shingada, MD**